Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of (S)-P-Hydroxyamphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamphetamine SCHEMBL125440 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL125442 | 1.00 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL219712 | 0.98 | TAAR1 (0.95) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL221649 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL28160718 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| (S)-P-Hydroxyamphetamine SCHEMBL9707065 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL219710 | 0.98 | TAAR1 (0.95) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL11539011 | 0.98 | TAAR1 (0.95) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL221291 | 0.98 | TAAR1 (0.95) | TAAR1SLC6A2SLC6A3SLC6A4MAOA | |
| Hydroxyamphetamine SCHEMBL221647 | 0.98 | TAAR1 (1.00) | TAAR1SLC6A2SLC6A3SLC6A4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112939900-B | Preparation method of buvaracetam intermediate | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-112939900-A | Preparation method of brivaracetam intermediate | 广东东阳光药业有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-101829598-B | Preparation method of acetylated glycosyl thiourea derivative and application thereof in isoquinoline acid synthesis | NANJING UNIVERSITY OF TECHNOLOGY | 2011-12-28 | — | — | CN | claimed |
| CN-102153520-A | Chiral 2- aryl substituted 1,3-oxazoline compounds and preparation method thereof | UNIV SHANGHAI | 2011-08-17 | — | — | CN | claimed |
| CN-101829598-A | Preparation method of acetylated glycosyl thiourea derivative and application thereof in isoquinoline acid synthesis | NANJING UNIVERSITY OF TECHNOLOGY | 2010-09-15 | — | — | CN | claimed |
| CN-112939900-B | Preparation method of buvaracetam intermediate | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-112500308-B | Golden amide alcohol ester and fluorinated derivative thereof, and preparation method and application thereof | 澳门科技大学 | 2023-10-03 | — | — | CN | disclosed |
| EP-2611771-B1 | SUBSTITUTED HETEROARYL- AND ARYLALKYNYL BENZENE DERIVATIVES AS ACC-INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-11-23 | — | — | EP | disclosed |
| US-9315792-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150125928-A1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BASF ENZYMES LLC | 2015-05-07 | — | — | US | disclosed |
| US-8835472-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-8835472-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-7217728-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217728-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20070066586-A1 | ANILINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2007-03-22 | — | — | US | disclosed |
| CN-1088912-A | The 4-amino-3-hydroxycarboxylic acid derivatives | SANDOZ LTD (CH) | 1994-07-06 | — | — | CN | disclosed |
| US-5017619-A | Anitdiabetic | HOFFMANN-LA ROCHE INC. (US) | 1991-05-21 | — | — | US | disclosed |
| EP-0198412-B1 | PHENETHANOL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1989-03-22 | — | — | EP | disclosed |
| EP-0198412-A1 | Phenethanol amine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-10-22 | — | — | EP | disclosed |
| US-4156010-A | TREATMENT OF GLAUCOMA | MERCK & CO., INC. (US) | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066586-A1 | ANILINE DERIVATIVES | SERPINB1, ACE, REN | TAAR1 1799/4885SLC6A2 435/4885SLC6A3 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.